Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by UMB Bank n.a.

UMB Bank n.a. lessened its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 93.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 747 shares of the biotechnology company's stock after selling 11,209 shares during the period. UMB Bank n.a.'s holdings in Axon Enterprise were worth $393,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Venturi Wealth Management LLC grew its holdings in Axon Enterprise by 2.7% in the fourth quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company's stock valued at $477,000 after purchasing an additional 21 shares during the last quarter. Beacon Pointe Advisors LLC grew its holdings in Axon Enterprise by 2.6% in the fourth quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company's stock valued at $513,000 after purchasing an additional 22 shares during the last quarter. Transcend Capital Advisors LLC grew its holdings in Axon Enterprise by 3.6% in the fourth quarter. Transcend Capital Advisors LLC now owns 726 shares of the biotechnology company's stock valued at $431,000 after purchasing an additional 25 shares during the last quarter. Fielder Capital Group LLC grew its holdings in Axon Enterprise by 2.2% in the fourth quarter. Fielder Capital Group LLC now owns 1,176 shares of the biotechnology company's stock valued at $699,000 after purchasing an additional 25 shares during the last quarter. Finally, Interchange Capital Partners LLC grew its holdings in Axon Enterprise by 1.9% in the fourth quarter. Interchange Capital Partners LLC now owns 1,310 shares of the biotechnology company's stock valued at $779,000 after purchasing an additional 25 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Trading Up 0.7%

Shares of Axon Enterprise stock traded up $5.43 during trading hours on Friday, reaching $780.63. The stock had a trading volume of 358,906 shares, compared to its average volume of 719,761. The firm has a 50 day simple moving average of $669.47 and a two-hundred day simple moving average of $621.53. The firm has a market capitalization of $60.77 billion, a price-to-earnings ratio of 201.71, a P/E/G ratio of 5.17 and a beta of 1.29. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 1 year low of $279.02 and a 1 year high of $806.64.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company's quarterly revenue was up 31.3% compared to the same quarter last year. During the same period last year, the business posted $1.15 EPS. As a group, equities research analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the transaction, the director now directly owns 1,627 shares of the company's stock, valued at approximately $899,275.44. The trade was a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Brittany Bagley sold 3,400 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the transaction, the chief financial officer now directly owns 131,833 shares in the company, valued at $92,283,100. This trade represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 43,969 shares of company stock worth $29,909,594. Corporate insiders own 4.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on AXON shares. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Barclays increased their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. The Goldman Sachs Group increased their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Finally, Needham & Company LLC raised their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.